Abstract
During the past decade, the arena of polymer therapeutics has acquired considerable interest and accompanied by advanced designs and chemical properties of polymer-drug conjugates. Various polymers, such as poly (ethylene glycol) (PEG), N-(2-hydroxypropyl) methacrylamide (HPMA), poly(glycolic acid) (PGA) and poly(lactide-co-glycolide) (PLGA) have been used successfully for clinical utilization from decades. These polymers are used in combination of drugs in such a manner that they target the specific tissues and thus the toxicity of drugs to other tissues is reduced. Presently, numerous polymer drug conjugates are under clinical trial for treatment of various diseases including cancer, diabetes, AIDS, rheumatoid arthritis etc. Many protein-polymer conjugates have been approved by FDA for clinical use but till date, no polymer-synthetic drug conjugate is approved by FDA, although many of them are undergoing final phase of clinical trials. This review highlights the recent advancements in the polymer-drug conjugates for treatment of various diseases and their preclinical and clinical status.
Keywords: Polymer, cancer, diabetes, conjugates, antiviral, disease.
Current Pharmaceutical Design
Title:Polymer Drug Conjugates: Recent Advancements in Various Diseases
Volume: 22 Issue: 19
Author(s): Jasbir Singh, Sapna Desai, Snehlata Yadav, Balasubramanian Narasimhan and Harmeet Kaur
Affiliation:
Keywords: Polymer, cancer, diabetes, conjugates, antiviral, disease.
Abstract: During the past decade, the arena of polymer therapeutics has acquired considerable interest and accompanied by advanced designs and chemical properties of polymer-drug conjugates. Various polymers, such as poly (ethylene glycol) (PEG), N-(2-hydroxypropyl) methacrylamide (HPMA), poly(glycolic acid) (PGA) and poly(lactide-co-glycolide) (PLGA) have been used successfully for clinical utilization from decades. These polymers are used in combination of drugs in such a manner that they target the specific tissues and thus the toxicity of drugs to other tissues is reduced. Presently, numerous polymer drug conjugates are under clinical trial for treatment of various diseases including cancer, diabetes, AIDS, rheumatoid arthritis etc. Many protein-polymer conjugates have been approved by FDA for clinical use but till date, no polymer-synthetic drug conjugate is approved by FDA, although many of them are undergoing final phase of clinical trials. This review highlights the recent advancements in the polymer-drug conjugates for treatment of various diseases and their preclinical and clinical status.
Export Options
About this article
Cite this article as:
Singh Jasbir, Desai Sapna, Yadav Snehlata, Narasimhan Balasubramanian and Kaur Harmeet, Polymer Drug Conjugates: Recent Advancements in Various Diseases, Current Pharmaceutical Design 2016; 22 (19) . https://dx.doi.org/10.2174/1381612822666160217125515
DOI https://dx.doi.org/10.2174/1381612822666160217125515 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Constructs and Targets in Clinical Development for Antibody- Based Cancer Therapy
Current Drug Targets Inhibition of sPLA2-IIA, C-reactive Protein or Complement: New Therapy for Patients with Acute Myocardial Infarction?
Cardiovascular & Hematological Disorders-Drug Targets Post-Wortmannin Era: Novel Phosphoinositide 3-Kinase Inhibitors with Potential Therapeutic Applications
Current Enzyme Inhibition Lipoxin and Synthetic Lipoxin Analogs: An Overview of Anti- Inflammatory Functions and New Concepts in Immunomodulation
Inflammation & Allergy - Drug Targets (Discontinued) Immunomodulatory and Anti-Inflammatory Activities of Statins
Endocrine, Metabolic & Immune Disorders - Drug Targets EPA and DHA Differentially Affect In Vitro Inflammatory Cytokine Release by Peripheral Blood Mononuclear Cells from Alzheimer’s Patients
Current Alzheimer Research Therapeutic Applications of Mesenchymal Stem Cells: A Comprehensive Review
Current Stem Cell Research & Therapy Psoriasis vulgaris and Psoriasis pustulosa – Epidemiology, Quality of Life, Comorbidities and Treatment
Current Rheumatology Reviews Modulating Co-Stimulation During Antigen Presentation to Enhance Cancer Immunotherapy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Risk Factors for Cardiovascular Disease in Psoriasis: Relation to Inflammation Assessed by the Severity and Duration of Illness
Inflammation & Allergy - Drug Targets (Discontinued) Potential Role of TRAIL in the Management of Autoimmune Diabetes Mellitus
Current Pharmaceutical Design Gender Specific Aspects of Cell Death in the Cardiovascular System
Current Pharmaceutical Design New Immunosuppressants: Immunosuppression and Immunomodulation
Medicinal Chemistry Reviews - Online (Discontinued) Interleukin-6 Trans-Signaling and Colonic Cancer Associated with Inflammatory Bowel Disease
Current Pharmaceutical Design Immunobiologic Agents in Dermatology
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Crohns Targeted Therapy: Myth or Real Goal?
Current Drug Discovery Technologies Crucial Role of Interferon-γ and Stimulated Macrophages in Cardiovascular Disease
Current Vascular Pharmacology Overview of Hyperuricaemia and Gout
Current Pharmaceutical Design Estrogen Receptor Beta in Cancer: an Attractive Target for Therapy
Current Pharmaceutical Design Antioxidant Properties of Crocus Sativus L. and Its Constituents and Relevance to Neurodegenerative Diseases; Focus on Alzheimer’s and Parkinson’s Disease
Current Neuropharmacology